Skip to content
OpenCapital
Get started

NovoCure NVCR Q3 2025 earnings

Reported October 30, 2025 · Before market open

Revenue$167.2MMiss by $7.2M
EPS-$0.33Beat by $0.09
Revenue estimate$174.4M
EPS estimate-$0.42

Next report

Date not yet announced

Financials

Q3 2025

Income statement

See full
Revenue$167.2M+7.8%
Gross profit$122.5M+2.3%
Operating income-$36.0M-12.2%
Net income-$37.3M-21.9%
EPS (diluted)-$0.33-17.9%

Balance sheet

See full
Cash & equivalents$342.1M+84.5%
Total debt$42.7M+102%
Total equity$341.3M-5.4%
Total assets$1.4B+11.4%

Cash flow

See full
Operating cash flow$20.6M+98.3%
CapEx$5.7M-47.1%
Free cash flow$14.9M+4,960%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.44B-14.2%
Enterprise value$1.15B-24.6%
P/S2.2×-0.7×

Profitability

See full
Gross margin75.4%-1.0pp
Operating margin-27.5%0.0pp
Net margin-27.7%+2.0pp
FCF margin-10.1%-2.0pp

Returns & leverage

See full
Return on equity-50.6%+19.1pp
Debt / equity0.1×+0.1×
Current ratio1.5×+0.1×

Versus estimates

Revenue

Q2 2026$183.6MBeat by $11.1MQ1 2026$174.1MBeat by $6.3MQ4 2025$174.4MIn line
Q3 2025$167.2MMiss by $7.2M
Q2 2025$158.8MIn lineQ1 2025$155.0MBeat by $1.1M

Diluted EPS

Q2 2026-$0.13Beat by $0.20Q1 2026-$0.62Miss by $0.11Q4 2025-$0.22Beat by $0.19
Q3 2025-$0.33Beat by $0.09
Q2 2025-$0.36Beat by $0.03Q1 2025-$0.31Beat by $0.16

Ask the moment NovoCure reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did NovoCure report Q3 2025 earnings?
NovoCure (NVCR) reported Q3 2025 earnings on October 30, 2025 before market open.
What were NovoCure's Q3 2025 revenue and EPS?
NovoCure reported revenue of $167.2M and eps of $-0.33 for Q3 2025.
Did NovoCure beat estimates in Q3 2025?
Revenue missed the consensus estimate of $174.4M by $7.2M. EPS beat the consensus estimate of $-0.42 by $0.09.
How did NovoCure's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 7.8% from $155.1M a year earlier and eps declined 17.9% from $-0.28.
Where can I find NovoCure's Q3 2025 SEC filings?
You can read the 10-Q periodic report (0001645113-25-000042) directly on SEC EDGAR. The filing index links above go to sec.gov.